% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Khandanpour:177382,
      author       = {C. Khandanpour and C. Eisfeld and S. C. Nimmagadda and M.
                      S. Raab and N. Weinhold and A. Seckinger and D. Hose and A.
                      Jauch and A. Försti$^*$ and K. Hemminki$^*$ and T.
                      Hielscher$^*$ and M. Hummel$^*$ and G. Lenz and H.
                      Goldschmidt and S. Huhn},
      title        = {{P}revalence of the {GFI}1-36{N} {SNP} in {M}ultiple
                      {M}yeloma {P}atients and {I}ts {I}mpact on the {P}rognosis.},
      journal      = {Frontiers in oncology},
      volume       = {11},
      issn         = {2234-943X},
      address      = {Lausanne},
      publisher    = {Frontiers Media},
      reportid     = {DKFZ-2021-02474},
      pages        = {757664},
      year         = {2021},
      abstract     = {Transcription factor Growth Factor Independence 1 (GFI1)
                      regulates the expression of genes important for survival,
                      proliferation and differentiation of hematopoietic cells. A
                      single nucleotide polymorphism (SNP) variant of GFI1
                      (GFI1-36N: serine replaced by asparagine at position 36),
                      has a prevalence of $5-7\%$ among healthy Caucasians and
                      $10-15\%$ in patients with myelodysplastic syndrome (MDS)
                      and acute myeloid leukaemia (AML) predisposing GFI-36N
                      carriers to these diseases. Since GFI1 is implicated in B
                      cell maturation and plasma cell (PC) development, we
                      examined its prevalence in patients with multiple myeloma
                      (MM), a haematological malignancy characterized by expansion
                      of clonal PCs. Strikingly, as in MDS and AML, we found that
                      the GFI1-36N had a higher prevalence among MM patients
                      compared to the controls. In subgroup analyses, GFI1-36N
                      correlates to a shorter overall survival of MM patients
                      characterized by the presence of t(4;14) translocation and
                      gain of 1q21 (≤3 copies). MM patients carrying gain of
                      1q21 (≥3 copies) demonstrated poor progression free
                      survival. Furthermore, gene expression analysis implicated a
                      role for GFI1-36N in epigenetic regulation and metabolism,
                      potentially promoting the initiation and progression of MM.},
      keywords     = {Gfi1 (Other) / SNP variant (Other) / multiple myeloma
                      (Other) / prevalance (Other) / prognosis (Other)},
      cin          = {B062 / HD01 / C050 / C060},
      ddc          = {610},
      cid          = {I:(DE-He78)B062-20160331 / I:(DE-He78)HD01-20160331 /
                      I:(DE-He78)C050-20160331 / I:(DE-He78)C060-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:34760702},
      pmc          = {pmc:PMC8574071},
      doi          = {10.3389/fonc.2021.757664},
      url          = {https://inrepo02.dkfz.de/record/177382},
}